Get started
Author

Lei Liang

Observed name: L. Liang
Observed institution: BeOne Medicines (Switzerland)
ORCID: 0000-0003-3870-1243
Observed ORCID: 0000-0003-3870-1243
OpenAlex ID: A5138759690
PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al. · Clinical Cancer Research · 3
PDF
Data from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S4 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S2 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S6 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S1 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S5 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Figure S3 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Material S2 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Tables S1-S15 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
Supplementary Material S1 from PET/CT-Guided Neoadjuvant Tislelizumab plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis
2026 · Yushang Yang, Xiaolong Yan, et al.
79P RATIONALE-304: Baseline tumour genomic alterations according to programmed death-ligand 1 (PD-L1) subgroups in nonsquamous non-small cell lung cancer (nsq-NSCLC) treated with first-line tislelizumab (TIS) plus chemotherapy (CT) vs CT alone
2026 · F. Cappuzzo, S. Lu, et al. · ESMO Open
Works count: 12
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type